Add this topic to your myFT Digest for news straight to your inbox
Anglo-Swedish pharmaceutical group wants to capitalise on its $39bn acquisition of Alexion
Plus, Olympics sponsors ask for delay and executives should listen to climate activists
Biotech acquisition has been approved in 10 countries including the US
AstraZeneca’s $39bn takeover of US bio group Alexion is a milestone moment in a busy year for M&A
Some shareholders support acquisition of rare disease specialist Alexion
Purchase of US rare disease specialist comes 6 years after pharma group saw off Pfizer takeover bid
Long-term results could be rewarding: investors should give this the benefit of the doubt
UK drugmaker to acquire US biotech specialising in rare disease treatment
Hedge fund renews assault on drugmaker after seeing window for sector M&A
Doubts hang over acquisitions struck when the industry was in the grip of an M&A frenzy
Biotech hopes to turn our bodies into ‘drug factories’ able to create own cures
US stocks make little progress at start of the week
Cautious sentiment risks cutting off funding for smaller biotechs
Companies with drugs already in clinical testing are being evaluated
Health providers are joining forces in an attempt to negotiate discounts
Investors are drawn to the low-volume, high-margin model
Hillary Clinton comments on ‘price-gouging’ hit the sector — but it was already vulnerable
Acquisition by drug developer latest sign of biotech buzz
International Edition